project . 2020 - 2022 . On going

SCORE

Swift COronavirus therapeutics REsponse

Open Access mandate for Publications European Commission

Funder: European CommissionProject code: 101003627 Call for proposal: H2020-SC1-PHE-CORONAVIRUS-2020
Funded under: H2020 | RIA Overall Budget: 2,627,550 EURFunder Contribution: 2,576,060 EUR
Status: On going
Start Date
01 Apr 2020
End Date
31 Mar 2022
Detailed project information (CORDIS)

Open Access mandate
Research Data: No

Link this project to...

Research outcomes
Deposit your research

Select content type to share

<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda__h2020::ac79baa81cc704f018c1dd7768537206&type=results"></script>');
-->
</script>

For further information contact us at helpdesk@openaire.eu

Download report

Select content type report to download

Summary
Publications
Research Data
Software
Other Research

Description

Coronavirus 2019-nCoV has become a worldwide public health emergency, and the lack of vaccines and drugs to immediately address this outbreak is painfully clear. Even if the epidemic can be stopped, the virus may return in the same or a modified form. More than vaccines and therapeutic antibodies, antiviral drugs can target highly conserved viral functions and have the broad-spectrum activity that is critical to combat current and future outbreaks. Since the 2003 SARS outbreak, as leading academic coronavirus researchers, we have collaborated to understand and inhibit coronavirus replication. We defined viral key functions, developed tools for inhibitor screenin...

Partners

AMU, University of Lübeck, Utrecht University, KUL, JANSSEN PHARMACEUTICA NV, Leiden University Medical Center, Helmholtz-Zentrum für Infektionsforschung GmbH, FDHA

Summary

Description

Partners

AMU, University of Lübeck, Utrecht University, KUL, JANSSEN PHARMACEUTICA NV, Leiden University Medical Center, Helmholtz-Zentrum für Infektionsforschung GmbH, FDHA

Any information missing or wrong?Report an Issue